Medtech-INSIDE – financial column, part 6: “Impact Investing: good return and do good!”
ESG, SRI, impact investing: when did this start, and what is its importance in the healthcare sector?
AMW GmbH expands management team and appoints Dr. Konstantin Petropoulos as Chief Executive Officer
AMW GmbH announced today that Dr. Konstantin Petropoulos has been appointed Chief Executive Officer (CEO) effective March 15, 2021 This expands Dr. Friedrich Tegel and Philipp Karbach to the existing management team.
Plattform Life Sciences, 01-2021: “Sentiment among investors and financing advisors 2021”
The industry magazine “Plattform Life Sciences” asked investors and financing advisors about the mood after the Corona year 2020 and, among others, asked SHS partner Manfred Ulmer-Weber about current financing trends and how life science investors like SHS see the world “after” COVID-19.
Speaking like an Investor – SHS Partner Dr. André Zimmermann in conversation with EIT Health
In a Podcast Caroline Sai of EIT Health and our Partner Andre Zimmermann are discussing in which ways the new MDR is heavily affecting the whole European Medtech area – from start-ups to established medium-sized companies. In addition, SHS is out-lining in which way medium-sized companies and investors can team-up not only to overcome the economical challenges of the MDR for Medtechs but to prosper.
Healthcare investor SHS sells stake in Crystal Laser Systems GmbH, a leading manufacturer of deep-UV laser systems for the healthcare, biotech and semiconductor industries
Tübingen-based healthcare investor SHS has provided capital and expertise to Crystal Laser Systems GmbH (CryLaS) on its way to becoming a leading, profitable provider of laser technology and is handing over the baton to Silver Investment Partners SIP CryLaS enjoys an excellent reputation worldwide in the healthcare, biotech and semiconductor sectors with pulsed and CW […]
medtech-INSIDE – financial column, part 5: “Digitization in medical technology: megatrend as megachance”
Digitization is one of the major challenges facing the medtech industry. Those who want to master them need courage, know-how and capital.
medtech-INSIDE – financial column, part 4: “The Brexit agreement: Light and shadow for SMEs in the healthcare sector”
‘Brexit is done’, as British Prime Minister Johnson wholeheartedly announced. But what does this mean for the SME-based healthcare and medtech sector? Read about it the current column by Dr. André Zimmermann.
Medtech investor SHS sold shares in Single Use Support GmbH
SHS Gesellschaft für Beteiligungsmanagement mbH (SHS) has sold its shares in the Austrian life science supplier Single Use Support GmbH (SUS) to Pall Corporation. SUS sets new standards for the transport of liquid substances in the medtech industry with its products, a success story Life science, biotech, pharmaceutical and medical device companies worldwide now use […]
SHS is investing in Blue Ocean Spine, a medtech firm based in Tuttlingen, Germany, and specializing in functional spinal implants
The Tübingen-based medtech investor SHS is investing in Blue Ocean Spine GmbH, a developer for 3D-printed spinal implants Blue Ocean Spine is developing a portfolio of new spinal implants that can be precisely adapted to patient needs in situ or administered without additional means of fixation such as screws For Guntmar Eisen, a serial entrepreneur […]
medtech-INSIDE – financial column, part 3: “Medtech in transition: Approval procedures in China”
With a population of around 1.4 billion, the People’s Republic of China is an enormously attractive market for medtech and life-science products. For foreign firms, this presents not only great opportunities but risks as well. By: Dr André Zimmermann, partner at Tübingen-based industry investor SHS. He has developed global connections in the medical technology sector […]